Seroprevalence of Hepatitis B and C and Associated Risk Factors among HIV-1 Infected Patients in a High Risk Border Region of South West Cameroon

Ndifontiayong Adamu Ndongho,Ndimumeh Jerimiah Mbogwe,Tume Christopher Bonglavnyuy,Kuiate Jules-Roger,Sokoudjou Jean Baptiste,Ali Innocent Mbulli

doi:10.23937/2474-3658/1510178

Ndifontiayong Adamu Ndongho, Ndimumeh Jerimiah Mbogwe + Show 4 more

Open Access

https://doi.org/10.23937/2474-3658/1510178

Copy DOI

Abstract

Coinfection of HIV with human retroviruses such as hepatitis B (HBV) and hepatitis C (HCV) has been associated with adverse liver disease outcomes including reduced survival, cancer and antiretroviral induced hepatotoxicity. In this study, we evaluated the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among HIV-infected individuals diagnosed within six months in South West Cameroon and identified risk factors of coinfection.

Highlights

Coinfection of human immunodeficiency virus (HIV) with human retroviruses such as hepatitis B (HBV) and hepatitis C (HCV) has been associated with adverse liver disease outcomes including reduced survival, cancer and antiretroviral induced hepatotoxicity
A history of blood transfusion was independently associated with hepatitis B or C infection
The aim of this study was to determine the seroprevalence of hepatitis B surface antigen (HBsAg) and HCVAb in newly diagnosed HIV-positive patients in Kumba Health District, South West region of Cameroon to contribute to better management of HIV patients in the region

Summary

Introduction

Coinfection of HIV with human retroviruses such as hepatitis B (HBV) and hepatitis C (HCV) has been associated with adverse liver disease outcomes including reduced survival, cancer and antiretroviral induced hepatotoxicity. Viral hepatitis has emerged as an important public health problem globally It is characterized by high prevalence, high burden of morbidity and mortality, and suboptimal diagnosis and management approaches [1,2]. Co-infections between HIV, HBV and/or HCV have been associated with reduced survival, increased risk of progression to liver diseases and increased risk of hepatotoxicity associated to antiretroviral therapy [3,4]. While varying in their transmission efficiencies, HIV, HBV and HCV share common routes of transmission, and as such, the prevalence of HBV and HCV are gener-

Objectives

Methods

Results

Conclusion